BASTIDE LE CONFORT MEDICAL (BLC.PA) Stock Fundamental Analysis
Europe - EPA:BLC - FR0000035370 - Common Stock
26.5 EUR
+1.05 (+4.13%)
BLC gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 30 industry peers in the Health Care Providers & Services industry. There are concerns on the financial health of BLC while its profitability can be described as average. BLC is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
BLC had positive earnings in the past year.
BLC had a positive operating cash flow in the past year.
Of the past 5 years BLC 4 years were profitable.
Each year in the past 5 years BLC had a positive operating cash flow.
1.2 Ratios
BLC's Return On Assets of 0.25% is on the low side compared to the rest of the industry. BLC is outperformed by 73.33% of its industry peers.
BLC has a Return On Equity of 2.25%. This is in the lower half of the industry: BLC underperforms 73.33% of its industry peers.
With a Return On Invested Capital value of 5.67%, BLC perfoms like the industry average, outperforming 56.67% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.25% | ||
| ROE | 2.25% | ||
| ROIC | 5.67% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
BLC has a Profit Margin of 0.36%. This is in the lower half of the industry: BLC underperforms 73.33% of its industry peers.
BLC's Profit Margin has declined in the last couple of years.
Looking at the Operating Margin, with a value of 7.87%, BLC is in the better half of the industry, outperforming 66.67% of the companies in the same industry.
In the last couple of years the Operating Margin of BLC has remained more or less at the same level.
BLC's Gross Margin of 67.54% is fine compared to the rest of the industry. BLC outperforms 73.33% of its industry peers.
In the last couple of years the Gross Margin of BLC has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.87% | ||
| PM (TTM) | 0.36% | ||
| GM | 67.54% |
OM growth 3Y5.49%
OM growth 5Y0.75%
PM growth 3Y-66.74%
PM growth 5Y-48.72%
GM growth 3Y1.15%
GM growth 5Y6.69%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so BLC is destroying value.
BLC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
BLC has an Altman-Z score of 1.27. This is a bad value and indicates that BLC is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of BLC (1.27) is worse than 66.67% of its industry peers.
BLC has a debt to FCF ratio of 9.33. This is a negative value and a sign of low solvency as BLC would need 9.33 years to pay back of all of its debts.
BLC has a Debt to FCF ratio of 9.33. This is comparable to the rest of the industry: BLC outperforms 50.00% of its industry peers.
A Debt/Equity ratio of 5.20 is on the high side and indicates that BLC has dependencies on debt financing.
The Debt to Equity ratio of BLC (5.20) is worse than 90.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.2 | ||
| Debt/FCF | 9.33 | ||
| Altman-Z | 1.27 |
ROIC/WACC0.97
WACC5.82%
2.3 Liquidity
A Current Ratio of 1.19 indicates that BLC should not have too much problems paying its short term obligations.
BLC has a Current ratio (1.19) which is comparable to the rest of the industry.
BLC has a Quick Ratio of 1.19. This is a bad value and indicates that BLC is not financially healthy enough and could expect problems in meeting its short term obligations.
BLC's Quick ratio of 0.96 is in line compared to the rest of the industry. BLC outperforms 56.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.19 | ||
| Quick Ratio | 0.96 |
3. Growth
3.1 Past
BLC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 158.33%, which is quite impressive.
BLC shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -46.37% yearly.
The Revenue has been growing slightly by 6.35% in the past year.
The Revenue has been growing slightly by 5.12% on average over the past years.
EPS 1Y (TTM)158.33%
EPS 3Y-66.43%
EPS 5Y-46.37%
EPS Q2Q%-107.14%
Revenue 1Y (TTM)6.35%
Revenue growth 3Y1.6%
Revenue growth 5Y5.12%
Sales Q2Q%9.55%
3.2 Future
BLC is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.22% yearly.
Based on estimates for the next years, BLC will show a small growth in Revenue. The Revenue will grow by 7.69% on average per year.
EPS Next Y41.62%
EPS Next 2Y16.22%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year3.87%
Revenue Next 2Y4.87%
Revenue Next 3Y9.77%
Revenue Next 5Y7.69%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
BLC is valuated quite expensively with a Price/Earnings ratio of 378.57.
Compared to the rest of the industry, the Price/Earnings ratio of BLC indicates a slightly more expensive valuation: BLC is more expensive than 76.67% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 25.91. BLC is valued rather expensively when compared to this.
Based on the Price/Forward Earnings ratio of 9.70, the valuation of BLC can be described as reasonable.
BLC's Price/Forward Earnings ratio is rather cheap when compared to the industry. BLC is cheaper than 93.33% of the companies in the same industry.
BLC's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 34.57.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 378.57 | ||
| Fwd PE | 9.7 |
4.2 Price Multiples
86.67% of the companies in the same industry are more expensive than BLC, based on the Enterprise Value to EBITDA ratio.
BLC's Price/Free Cash Flow ratio is rather cheap when compared to the industry. BLC is cheaper than 83.33% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 4.33 | ||
| EV/EBITDA | 5.97 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
BLC's earnings are expected to grow with 16.22% in the coming years. This may justify a more expensive valuation.
PEG (NY)9.1
PEG (5Y)N/A
EPS Next 2Y16.22%
EPS Next 3YN/A
5. Dividend
5.1 Amount
BLC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EPA:BLC (11/14/2025, 11:59:05 AM)
26.5
+1.05 (+4.13%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners11.14%
Inst Owner ChangeN/A
Ins Owners1.58%
Ins Owner ChangeN/A
Market Cap195.31M
Revenue(TTM)491.18M
Net Income(TTM)1.71M
Analysts83.33
Price Target36.72 (38.57%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0.22
Dividend Growth(5Y)-3.5%
DP42.86%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)9.09%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)4.84%
EPS NY rev (3m)-20.09%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)2%
Revenue NY rev (3m)-14.29%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 378.57 | ||
| Fwd PE | 9.7 | ||
| P/S | 0.41 | ||
| P/FCF | 4.33 | ||
| P/OCF | 1.74 | ||
| P/B | 2.57 | ||
| P/tB | N/A | ||
| EV/EBITDA | 5.97 |
EPS(TTM)0.07
EY0.26%
EPS(NY)2.73
Fwd EY10.31%
FCF(TTM)6.12
FCFY23.09%
OCF(TTM)15.22
OCFY57.42%
SpS64.09
BVpS10.32
TBVpS-19.15
PEG (NY)9.1
PEG (5Y)N/A
Graham Number4.03
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.25% | ||
| ROE | 2.25% | ||
| ROCE | 7.72% | ||
| ROIC | 5.67% | ||
| ROICexc | 5.68% | ||
| ROICexgc | 10.34% | ||
| OM | 7.87% | ||
| PM (TTM) | 0.36% | ||
| GM | 67.54% | ||
| FCFM | 9.55% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y5.49%
OM growth 5Y0.75%
PM growth 3Y-66.74%
PM growth 5Y-48.72%
GM growth 3Y1.15%
GM growth 5Y6.69%
F-Score5
Asset Turnover0.7
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.2 | ||
| Debt/FCF | 9.33 | ||
| Debt/EBITDA | 3.88 | ||
| Cap/Depr | 103.59% | ||
| Cap/Sales | 14.19% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 110.05% | ||
| Profit Quality | 2640.05% | ||
| Current Ratio | 1.19 | ||
| Quick Ratio | 0.96 | ||
| Altman-Z | 1.27 |
F-Score5
WACC5.82%
ROIC/WACC0.97
Cap/Depr(3y)92.61%
Cap/Depr(5y)91.81%
Cap/Sales(3y)11.59%
Cap/Sales(5y)11.33%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)158.33%
EPS 3Y-66.43%
EPS 5Y-46.37%
EPS Q2Q%-107.14%
EPS Next Y41.62%
EPS Next 2Y16.22%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)6.35%
Revenue growth 3Y1.6%
Revenue growth 5Y5.12%
Sales Q2Q%9.55%
Revenue Next Year3.87%
Revenue Next 2Y4.87%
Revenue Next 3Y9.77%
Revenue Next 5Y7.69%
EBIT growth 1Y-6.92%
EBIT growth 3Y7.18%
EBIT growth 5Y5.9%
EBIT Next Year133.33%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y31.91%
FCF growth 3Y107.15%
FCF growth 5Y33.43%
OCF growth 1Y27.54%
OCF growth 3Y17.38%
OCF growth 5Y14.21%
BASTIDE LE CONFORT MEDICAL / BLC.PA FAQ
Can you provide the ChartMill fundamental rating for BASTIDE LE CONFORT MEDICAL?
ChartMill assigns a fundamental rating of 4 / 10 to BLC.PA.
What is the valuation status for BLC stock?
ChartMill assigns a valuation rating of 5 / 10 to BASTIDE LE CONFORT MEDICAL (BLC.PA). This can be considered as Fairly Valued.
Can you provide the profitability details for BASTIDE LE CONFORT MEDICAL?
BASTIDE LE CONFORT MEDICAL (BLC.PA) has a profitability rating of 4 / 10.
What is the valuation of BASTIDE LE CONFORT MEDICAL based on its PE and PB ratios?
The Price/Earnings (PE) ratio for BASTIDE LE CONFORT MEDICAL (BLC.PA) is 378.57 and the Price/Book (PB) ratio is 2.57.
How sustainable is the dividend of BASTIDE LE CONFORT MEDICAL (BLC.PA) stock?
The dividend rating of BASTIDE LE CONFORT MEDICAL (BLC.PA) is 0 / 10 and the dividend payout ratio is 42.86%.